Comparative Pharmacology
Head-to-head clinical analysis: MEDIHALER EPI versus MEDIHALER ISO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEDIHALER EPI versus MEDIHALER ISO.
MEDIHALER-EPI vs MEDIHALER-ISO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine is a direct-acting sympathomimetic amine that acts on alpha- and beta-adrenergic receptors. Alpha-adrenergic stimulation increases peripheral vascular resistance and blood pressure, while beta-adrenergic stimulation increases heart rate, myocardial contractility, and bronchodilation.
Isoproterenol acts as a non-selective beta-adrenergic agonist, stimulating both beta-1 and beta-2 receptors, leading to increased heart rate, contractility, and bronchodilation.
Each inhalation delivers 0.22 mg epinephrine (base equivalent). Acute asthma exacerbation: 1-2 inhalations every 4 hours as needed. Maximum 12 inhalations in 24 hours.
1-2 inhalations (80-160 mcg) sublingually or by inhalation as needed for angina; maximum 6 inhalations per day.
None Documented
None Documented
The terminal elimination half-life of epinephrine is approximately 2-3 minutes. Clinically, this short half-life necessitates repeated dosing or continuous infusion for sustained effect during anaphylaxis or cardiac arrest.
Terminal half-life: 2 hours (range 1.5–3 hours) after inhalation; prolonged in hepatic impairment
Epinephrine is primarily metabolized in the liver and other tissues by catechol-O-methyltransferase (COMT) and monoamine oxidase (MAO). The metabolites, including metanephrine and vanillylmandelic acid (VMA), are excreted in urine. Less than 5% of the drug is excreted unchanged in urine. Fecal elimination is negligible.
Renal: 60% unchanged; biliary/fecal: 30% as conjugated metabolites
Category C
Category C
Adrenergic Bronchodilator
Adrenergic Bronchodilator